{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:17:42Z","timestamp":1793089062398,"version":"4.5.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to evaluate the influence of the timing for bromocriptine withdrawal in pregnant women with pituitary prolactin-secreting microadenomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study,188 pregnant women diagnosed with pituitary prolactin-secreting microadenomas, who delivered between January 2005 and June 2023 were categorized into four groups based on their use and duration of bromocriptine therapy. Their pregnancy and neonatal outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 188 patients, the incidence of neurological symptoms during pre-pregnancy varied significantly across the groups (P = 0.000), with the highest prevalence in Group A (21.7%) and minimal to no symptoms in other Groups. The live birth rates and miscarriage rates did not show statistically significant differences across the groups (P = 0.508). Premature birth rates were 6.5%, 6.2%, 13.2%, and 0% for Groups A, B, C, and D, respectively. Notably, the incidence of small-for-gestational-age (SGA) infants increased with prolonged bromocriptine use, while large-for-gestational-age (LGA) rates decreased, though these trends were not statistically significant (P = 0.068). Median gestational age differed significantly across groups (P = 0.000), but neonatal weights remained comparable (P = 0.471).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Discontinuation of bromocriptine after pregnancy confirmation is generally safe for patients with pituitary prolactin-secreting microadenomas. However, for patients with pre-existing neurological or ophthalmological symptoms, or those untreated prior to pregnancy, close monitoring and potential continuation of dopamine agonist therapy are waranted. Bromocriptine exposure throughout pregnancy does not increase the risk of miscarriage, congenital anomalies, or adverse neonatal outcomes. But further prospective studies are needed to elucidate the long-term effects of bromocriptine on fetal development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1806870","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:13:52Z","timestamp":1775103232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of bromocriptine withdrawal timing on pregnancy outcomes in patients with pituitary prolactin-secreting microadenomas: a real-world retrospective study of 188 pregnancies in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiao","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Department of Obstetrics and Gynaecology, The First People\u2019s Hospital of Shuangliu District","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Department of Obstetrics and Gynaecology, Qamdo People\u2019s Hospital of Tibet Autonomous Region","place":["Qamdo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital\/West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/cen.14162","article-title":"Evolution of macroprolactinomas during pregnancy: a cohort study of 85 pregnancies","volume":"92","author":"Barraud","year":"2020","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s0015-0282(16)43929-4","article-title":"Outcome of pregnancy in women with pituitary adenoma","volume":"31","author":"Gemzell","year":"1979","journal-title":"Fertil. Steril."},{"key":"B4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00404-014-3210-z","article-title":"Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database","volume":"290","author":"Hurault-Delarue","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects","volume":"65","author":"Krupp","year":"1987","journal-title":"Klin. Wochenschr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clineuro.2018.11.024","article-title":"Fertility after transsphenoidal surgery in patients with prolactinomas: a meta-analysis","volume":"176","author":"Lamba","year":"2019","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ando.2016.04.001","article-title":"Prolactinoma and pregnancy: from the wish of conception to lactation","volume":"77","author":"Maiter","year":"2016","journal-title":"Ann. Endocrinol. Paris."},{"key":"B9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s0015-0282(16)47888-x","article-title":"Pregnancy in hyperprolactinemic women","volume":"41","author":"Ruiz-Velasco","year":"1984","journal-title":"Fertil. Steril."},{"key":"B13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant' Anna","year":"2020","journal-title":"Pituitary"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.1982.03320360039028","article-title":"Surveillance of bromocriptine in pregnancy","volume":"247","author":"Turkalj","year":"1982","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jocn.2015.03.058","article-title":"Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges","volume":"22","author":"Wong","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"B16","volume-title":"Obstetrics and gynecology [M]","author":"Xie","year":"2018"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:13:55Z","timestamp":1775103235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":16,"alternative-id":["10.3389\/fphar.2026.1806870"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1806870","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1806870"}}